Abstract
Background and aims: MiR–21 and miR–122 have been identified as promising biomarkers in hepatocellular carcinoma (HCC). We aimed to evaluate their prognostic role in HCC patients treated with transarterial chemoembolization (TACE), a methodology inducing liver ischemia, and the link, if present, with an angiogenesis biomarker (HIF-1alpha).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
